Phospho-ALK (Tyr1507) Antibody [P14J22]

Application: Reactivity: Human

Lane 1: KARPAS-299, Lane 2: KARPAS-299 (Crizotinib, 1 μM, 1 h)

Usage Information

Dilution
WB1:1000 IP1:100 IF1:400 FCM1:200

Application
WB, IP, IF, FCM

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
80 kDa

Datasheet & SDS

Biological Description

Specificity
Phospho-ALK (Tyr1507) Antibody [P14J22] detects endogenous levels of total ALK protein only when it is phosphorylated at Tyr1507.

Clone
P14J22

Synonym(s)
ALK tyrosine kinase receptor; Anaplastic lymphoma kinase; CD246; ALK

Background
Phospho‑ALK (Tyr1507) marks a functionally critical autophosphorylation site on the intracellular tyrosine kinase domain of anaplastic lymphoma kinase (ALK), a neuronal‑type receptor tyrosine kinase activated by ligands such as pleiotrophin and ALKAL family proteins in the nervous system and by oncogenic ALK‑fusion proteins in cancer. In the full‑length receptor, tyrosine‑1507 lies within a canonical NPXpY motif that, when phosphorylated, recruits SH2‑domain‑ and PTB‑domain‑containing adaptor proteins, most notably the docking proteins Shc, FRS2‑α, and FRS2‑β, which in turn bridge activated ALK to the Ras‑ERK (MAPK) and PI3K‑Akt signaling axes. Antibody‑mediated or ligand‑dependent activation of ALK drives phosphorylation at Tyr1507, promotes Shc and FRS2 recruitment and phosphorylation, and supports sustained ERK activation that underlies neuronal‑like differentiation and mitogenic responses. The equivalent phospho‑site (Tyr567) in the NPM‑ALK fusion is constitutively phosphorylated and required for efficient engagement of Shc and FRS2, thereby sustaining downstream proliferative and survival‑signaling pathways that contribute to lymphoma pathogenesis.

Background

Phospho‑ALK (Tyr1507) marks a functionally critical autophosphorylation site on the intracellular tyrosine kinase domain of anaplastic lymphoma kinase (ALK), a neuronal‑type receptor tyrosine kinase activated by ligands such as pleiotrophin and ALKAL family proteins in the nervous system and by oncogenic ALK‑fusion proteins in cancer. In the full‑length receptor, tyrosine‑1507 lies within a canonical NPXpY motif that, when phosphorylated, recruits SH2‑domain‑ and PTB‑domain‑containing adaptor proteins, most notably the docking proteins Shc, FRS2‑α, and FRS2‑β, which in turn bridge activated ALK to the Ras‑ERK (MAPK) and PI3K‑Akt signaling axes. Antibody‑mediated or ligand‑dependent activation of ALK drives phosphorylation at Tyr1507, promotes Shc and FRS2 recruitment and phosphorylation, and supports sustained ERK activation that underlies neuronal‑like differentiation and mitogenic responses. The equivalent phospho‑site (Tyr567) in the NPM‑ALK fusion is constitutively phosphorylated and required for efficient engagement of Shc and FRS2, thereby sustaining downstream proliferative and survival‑signaling pathways that contribute to lymphoma pathogenesis.

References
https://pubmed.ncbi.nlm.nih.gov/23889739/ https://pubmed.ncbi.nlm.nih.gov/17274988/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%